Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
June 1, 2020 6:00 AM EDTPHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Adaptimmune)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (ADSs) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the... More
